conventional therapy plus low dose hUC-MSCs treatment
BKCR-LD-1.0(2010)
Phase 2 mab completed
Quick answer
conventional therapy plus low dose hUC-MSCs treatment for Liver Cirrhosis is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Liver Cirrhosis
- Phase
- Phase 2
- Modality
- mab
- Status
- completed